Pulmocide Attracts $27.5M Series A for Respiratory Infections
By Nuala Moran
Monday, November 25, 2013
LONDON – Pulmocide Ltd. has raised £17 million (US$27.5 million) in Series A funding to embark on the discovery of a new generation of inhaled treatments for serious viral and fungal infections of the respiratory tract. If that is a large amount of money for the first round of a biotech company with no compounds, the reason lies in the expertise and track record of the founders, who are both former Glaxosmithkline plc executives.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.